Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 14;11(6):1578–1586. doi: 10.1111/1759-7714.13432

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Kaplan‐Meier curves according to the lung immune prognostic index (LIPI) in ED‐SCLC patients. (a) The median progression‐free survival (PFS) of the LIPI 0 group and LIPI 1 group was significantly longer than that of the LIPI 2 group (6.6 months vs. 4.0 months, P = 0.006 and 5.5 months vs. 4.0 months, P = 0.015, respectively) ( ) LIPI 0 group, ( ) LIPI 1 group, ( ) LIPI 2 group. The median PFS of the LIPI 0 group was not significantly different from that of the LIPI 1 group (P = 0.725). (b) The median overall survival (OS) of the LIPI 0 group was significantly longer than that of the LIPI 1 group and LIPI 2 group (17.1 months vs. 11.6 months, P = 0.009 and 17.1 months vs. 5.9 months, P < 0.001, respectively) ( ) LIPI 0 group, ( ) LIPI 1 group, ( ) LIPI 2 group. The median OS of the LIPI 1 group was significantly longer than that of the LIPI 2 group (P = 0.001).

Inline graphic — Kaplan‐Meier curves according to the lung immune prognostic index (LIPI) in ED‐SCLC patients. (a) The median progression‐free survival (PFS) of the LIPI 0 group and LIPI 1 group was significantly longer than that of the LIPI 2 group (6.6 months vs. 4.0 months, P = 0.006 and 5.5 months vs. 4.0 months, P = 0.015, respectively) ( ) LIPI 0 group, ( ) LIPI 1 group, ( ) LIPI 2 group. The median PFS of the LIPI 0 group was not significantly different from that of the LIPI 1 group (P = 0.725). (b) The median overall survival (OS) of the LIPI 0 group was significantly longer than that of the LIPI 1 group and LIPI 2 group (17.1 months vs. 11.6 months, P = 0.009 and 17.1 months vs. 5.9 months, P < 0.001, respectively) ( ) LIPI 0 group, ( ) LIPI 1 group, ( ) LIPI 2 group. The median OS of the LIPI 1 group was significantly longer than that of the LIPI 2 group (P = 0.001).